{"filing":{"accession_number":"0001682852-26-000134","cik":"0001682852","ticker":"MRNA","company_name":"Moderna, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"mrna-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000134/mrna-20260706.htm"},"events":[{"id":16591,"run_id":14823,"accession_number":"0001682852-26-000134","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. McDonnell brings extensive CFO experience from major life sciences companies including Biogen and IQVIA.","company_name":"Moderna, Inc.","ticker":"MRNA","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14740,"accession_number":"0001682852-26-000134","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. The disclosure centers on the principal action of a person taking a role—a director appointment—rather than a departure or compensation arrangement. McDonnell's extensive CFO experience at major life sciences companies (Biogen, IQVIA, Intelsat) and his appointment to the Audit Committee make this material to investors assessing board composition and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:39.777071+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14741,"accession_number":"0001682852-26-000134","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Michael McDonnell to Moderna's Board of Directors, effective July 8, 2026, with assignment to the Audit Committee. This is a clear executive/governance appointment of a director with substantial financial and public company experience (former CFO of Biogen and IQVIA). Board appointments are material governance events affecting the composition and oversight of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:39.777071+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14740,"accession_number":"0001682852-26-000134","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. The disclosure centers on the principal action of a person taking a role—a director appointment—rather than a departure or compensation arrangement. McDonnell's extensive CFO experience at major life sciences companies (Biogen, IQVIA, Intelsat) and his appointment to the Audit Committee make this material to investors assessing board composition and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:39.777071+00:00","company_name":"Moderna, Inc.","ticker":"MRNA","filing_date":"2026-07-08"},{"id":14741,"accession_number":"0001682852-26-000134","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Michael McDonnell to Moderna's Board of Directors, effective July 8, 2026, with assignment to the Audit Committee. This is a clear executive/governance appointment of a director with substantial financial and public company experience (former CFO of Biogen and IQVIA). Board appointments are material governance events affecting the composition and oversight of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:09:39.777071+00:00","company_name":"Moderna, Inc.","ticker":"MRNA","filing_date":"2026-07-08"}]}